Table 4.
Changes in treatment pattern according to severity (GOLD stages) during the 12-month follow-up in patients in both groups matched for age, sex, FEV1%, previous history of exacerbations, history of asthma and duration of treatment
| Patients starting on LAMA N = 524 | Patients starting on LABA/LAMA N = 524 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Gold 1 N = 56 | Gold 2 N = 325 | Gold 3 N = 118 | Gold 4 N = 25 | Total | Gold 1 N = 42 | Gold 2 N = 333 | Gold 3 N = 132 | Gold 4 N = 17 | |
| LAMA | 386 (73.7) | 47 (83.9) | 245 (75.4) | 78 (66.1) | 16 (64) | 44 (8.4) | 6 (14.3) | 31 (9.3) | 7 (5.3) | 0 |
| LABA | 7 (1.3) | 0 | 5 (1.5) | 2 (1.7) | 0 | 36 (6.9) | 1 (2.4) | 30 (9) | 5 (3.8) | 0 |
| ICS | 5 (1) | 1 (1.8) | 2 (0.6) | 1 (0.8) | 1 (4) | 7 (1.3) | 1 (2.4) | 4 (1.2) | 2 (1.5) | 0 |
| LABA/LAMA | 39 (7.4) | 3 (5.4) | 20 (6.2) | 16 (13.6) | 0 | 345 (65.8) | 28 (66.7) | 209 (62.8) | 95 (72) | 13 (76.5) |
| LABA/ICS | 22 (4.2) | 1 (1.8) | 12 (3.7) | 5 (4.2) | 4 (16) | 25 (4.8) | 1 (2.4) | 13 (3.9) | 8 (6.1) | 3 (17.6) |
| LAMA/ICS | 7 (1.3) | 0 | 4 (1.2) | 3 (2.5) | 0 | 0 | 0 | 0 | 0 | 0 |
| LAMA/LABA/ICS | 29 (5.5) | 1 (1.8) | 17 (5.2) | 8 (6.8) | 3 (12) | 33 (6.3) | 2 (4.8) | 20 (6) | 10 (7.6) | 1 (5.9) |
| No treatment | 29 (5.5) | 3 (5.4) | 20 (6.2) | 5 (4.2) | 1 (4) | 34 (6.5) | 3 (7.1) | 26 (7.8) | 5 (3.8) | 0 |
Data are expressed as n (%)
LABA long-acting beta-2 agonist, LAMA long-acting anti-muscarinic, ICS inhaled corticosteroid